Eupraxia Pharmaceuticals Inc. (EPRX)
NASDAQ: EPRX · Real-Time Price · USD
8.20
+0.15 (1.86%)
Feb 26, 2026, 3:13 PM EST - Market open
Eupraxia Pharmaceuticals Market Cap
Eupraxia Pharmaceuticals has a market cap or net worth of $485.75 million as of February 26, 2026. Its market cap has increased by 331.02% in one year.
Market Cap
485.75M
Enterprise Value
426.00M
1-Year Change
331.02%
Ranking
Category
Stock Price
$8.20
Market Cap Chart
Since March 9, 2021, Eupraxia Pharmaceuticals's market cap has increased from $61.62M to $485.75M, an increase of 688.31%. That is a compound annual growth rate of 51.51%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 25, 2026 | 485.75M | 27.42% |
| Dec 31, 2025 | 381.21M | 241.41% |
| Dec 31, 2024 | 111.66M | 0.72% |
| Dec 29, 2023 | 110.86M | 90.37% |
| Dec 30, 2022 | 58.23M | 111.19% |
| Dec 31, 2021 | 27.57M | -55.25% |
| Mar 9, 2021 | 61.62M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Lexeo Therapeutics | 502.88M |
| Zevra Therapeutics | 502.74M |
| Tenax Therapeutics | 502.26M |
| Lyell Immunopharma | 498.81M |
| Solid Biosciences | 491.61M |
| Vanda Pharmaceuticals | 489.41M |
| Invivyd | 482.20M |
| Prothena Corporation | 478.01M |